369 related articles for article (PubMed ID: 26133222)
1. Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging.
Jeon TY; Kim CK; Kim JH; Im GH; Park BK; Lee JH
Br J Radiol; 2015 Sep; 88(1053):20150163. PubMed ID: 26133222
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric MR diffusion-weighted imaging for monitoring the ultra-early treatment effect of sorafenib in human hepatocellular carcinoma xenografts.
Chen X; Ma Z; Huang Y; He L; Liang C; Shi C; Zhang Z; Liang C; Liu Z
J Magn Reson Imaging; 2017 Jul; 46(1):248-256. PubMed ID: 27783444
[TBL] [Abstract][Full Text] [Related]
3. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
Hahn OM; Yang C; Medved M; Karczmar G; Kistner E; Karrison T; Manchen E; Mitchell M; Ratain MJ; Stadler WM
J Clin Oncol; 2008 Oct; 26(28):4572-8. PubMed ID: 18824708
[TBL] [Abstract][Full Text] [Related]
4. Combined diffusion-weighted, blood oxygen level-dependent, and dynamic contrast-enhanced MRI for characterization and differentiation of renal cell carcinoma.
Notohamiprodjo M; Staehler M; Steiner N; Schwab F; Sourbron SP; Michaely HJ; Helck AD; Reiser MF; Nikolaou K
Acad Radiol; 2013 Jun; 20(6):685-93. PubMed ID: 23664397
[TBL] [Abstract][Full Text] [Related]
5. Assessment of early response to concurrent chemoradiotherapy in cervical cancer: value of diffusion-weighted and dynamic contrast-enhanced MR imaging.
Park JJ; Kim CK; Park SY; Simonetti AW; Kim E; Park BK; Huh SJ
Magn Reson Imaging; 2014 Oct; 32(8):993-1000. PubMed ID: 24970025
[TBL] [Abstract][Full Text] [Related]
6. Monitoring anti-angiogenic therapy in colorectal cancer murine model using dynamic contrast-enhanced MRI: comparing pixel-by-pixel with region of interest analysis.
Haney CR; Fan X; Markiewicz E; Mustafi D; Karczmar GS; Stadler WM
Technol Cancer Res Treat; 2013 Feb; 12(1):71-8. PubMed ID: 22905809
[TBL] [Abstract][Full Text] [Related]
7. Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy (SABR) of primary renal cell carcinoma.
Reynolds HM; Parameswaran BK; Finnegan ME; Roettger D; Lau E; Kron T; Shaw M; Chander S; Siva S
PLoS One; 2018; 13(8):e0202387. PubMed ID: 30114235
[TBL] [Abstract][Full Text] [Related]
8. Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts.
Moestue SA; Huuse EM; Lindholm EM; Bofin A; Engebraaten O; Mælandsmo GM; Akslen LA; Gribbestad IS
J Magn Reson Imaging; 2013 Nov; 38(5):1043-53. PubMed ID: 23908122
[TBL] [Abstract][Full Text] [Related]
9. Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy.
Hahn SY; Ko EY; Han BK; Shin JH; Ko ES
Eur J Radiol; 2014 Feb; 83(2):283-8. PubMed ID: 24315957
[TBL] [Abstract][Full Text] [Related]
10. Dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging in the activity staging of terminal ileum Crohn's disease.
Wu YC; Xiao ZB; Lin XH; Zheng XY; Cao DR; Zhang ZS
World J Gastroenterol; 2020 Oct; 26(39):6057-6073. PubMed ID: 33132655
[TBL] [Abstract][Full Text] [Related]
11. Use of diffusion-weighted, intravoxel incoherent motion, and dynamic contrast-enhanced MR imaging in the assessment of response to radiotherapy of lytic bone metastases from breast cancer.
Gaeta M; Benedetto C; Minutoli F; D'Angelo T; Amato E; Mazziotti S; Racchiusa S; Mormina E; Blandino A; Pergolizzi S
Acad Radiol; 2014 Oct; 21(10):1286-93. PubMed ID: 25088834
[TBL] [Abstract][Full Text] [Related]
12. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts.
Tran A; Koh TS; Prawira A; Ho RZW; Le TBU; Vu TC; Hartano S; Teo XQ; Chen WC; Lee P; Thng CH; Huynh H
Mol Imaging Biol; 2021 Feb; 23(1):70-83. PubMed ID: 32909245
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of tumor microvascular response to brivanib by dynamic contrast-enhanced 7-T MRI in an orthotopic xenograft model of hepatocellular carcinoma.
Song KD; Choi D; Lee JH; Im GH; Yang J; Kim JH; Lee WJ
AJR Am J Roentgenol; 2014 Jun; 202(6):W559-66. PubMed ID: 24848850
[TBL] [Abstract][Full Text] [Related]
14. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma.
Flaherty KT; Rosen MA; Heitjan DF; Gallagher ML; Schwartz B; Schnall MD; O'Dwyer PJ
Cancer Biol Ther; 2008 Apr; 7(4):496-501. PubMed ID: 18219225
[TBL] [Abstract][Full Text] [Related]
15. Prediction of the response of ocular adnexal lymphoma to chemotherapy using combined pretreatment dynamic contrast-enhanced and diffusion-weighted MRI.
Guo P; Liu Z; Yan F; Wang J; Wei L; Lv H; Wang Z; Xian J
Acta Radiol; 2016 Dec; 57(12):1490-1496. PubMed ID: 27012277
[TBL] [Abstract][Full Text] [Related]
16. Dynamic contrast-enhanced and diffusion-weighted MRI of estrogen receptor-positive invasive breast cancers: Associations between quantitative MR parameters and Ki-67 proliferation status.
Shin JK; Kim JY
J Magn Reson Imaging; 2017 Jan; 45(1):94-102. PubMed ID: 27313102
[TBL] [Abstract][Full Text] [Related]
17. Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis.
Bäuerle T; Bartling S; Berger M; Schmitt-Gräff A; Hilbig H; Kauczor HU; Delorme S; Kiessling F
Eur J Radiol; 2010 Feb; 73(2):280-7. PubMed ID: 19070445
[TBL] [Abstract][Full Text] [Related]
18. Multiparametric approach with diffusion-weighted imaging and dynamic contrast-enhanced MRI: a comparison study for differentiating between benign and malignant bone lesions in adults.
Oh E; Yoon YC; Kim JH; Kim K
Clin Radiol; 2017 Jul; 72(7):552-559. PubMed ID: 28325514
[TBL] [Abstract][Full Text] [Related]
19. The application of dynamic contrast-enhanced MRI and diffusion-weighted MRI in patients with maxillofacial tumors.
Kitamoto E; Chikui T; Kawano S; Ohga M; Kobayashi K; Matsuo Y; Yoshiura T; Obara M; Honda H; Yoshiura K
Acad Radiol; 2015 Feb; 22(2):210-6. PubMed ID: 25442795
[TBL] [Abstract][Full Text] [Related]
20. Role of quantitative magnetic resonance imaging parameters in the evaluation of treatment response in malignant tumors.
Xu QG; Xian JF
Chin Med J (Engl); 2015 Apr; 128(8):1128-33. PubMed ID: 25881611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]